195 related articles for article (PubMed ID: 27137694)
1. [Resistance to anti-angiogenic therapy: a clinical and scientific current issue].
Gu Y; Lu H; Boisson-Vidal C; Li H; Bousquet G; Janin A; Di Benedetto M
Med Sci (Paris); 2016 Apr; 32(4):370-7. PubMed ID: 27137694
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
3. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
4. Latest Results for Anti-Angiogenic Drugs in Cancer Treatment.
Frandsen S; Kopp S; Wehland M; Pietsch J; Infanger M; Grimm D
Curr Pharm Des; 2016; 22(39):5927-5942. PubMed ID: 27426129
[TBL] [Abstract][Full Text] [Related]
5. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
Gacche RN; Meshram RJ
Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
[TBL] [Abstract][Full Text] [Related]
6. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.
Rapisarda A; Melillo G
Drug Resist Updat; 2009 Jun; 12(3):74-80. PubMed ID: 19394890
[TBL] [Abstract][Full Text] [Related]
7. Role of the tumor stroma in resistance to anti-angiogenic therapy.
Huijbers EJ; van Beijnum JR; Thijssen VL; Sabrkhany S; Nowak-Sliwinska P; Griffioen AW
Drug Resist Updat; 2016 Mar; 25():26-37. PubMed ID: 27155374
[TBL] [Abstract][Full Text] [Related]
8. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
9. Vaccination approach to anti-angiogenic treatment of cancer.
Wentink MQ; Huijbers EJ; de Gruijl TD; Verheul HM; Olsson AK; Griffioen AW
Biochim Biophys Acta; 2015 Apr; 1855(2):155-71. PubMed ID: 25641676
[TBL] [Abstract][Full Text] [Related]
10. Vessel co-option and resistance to anti-angiogenic therapy.
Kuczynski EA; Reynolds AR
Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
[TBL] [Abstract][Full Text] [Related]
11. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
12. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis: a target for cancer therapy.
Tortora G; Melisi D; Ciardiello F
Curr Pharm Des; 2004; 10(1):11-26. PubMed ID: 14754402
[TBL] [Abstract][Full Text] [Related]
14. Redundant angiogenic signaling and tumor drug resistance.
Gacche RN; Assaraf YG
Drug Resist Updat; 2018 Jan; 36():47-76. PubMed ID: 29499837
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors.
Mitchell DC; Bryan BA
J Cell Biochem; 2010 Oct; 111(3):543-53. PubMed ID: 20626031
[TBL] [Abstract][Full Text] [Related]
16. [Tumor angiogenesis: recent progress and remaining challenges].
Feige JJ
Bull Cancer; 2010 Nov; 97(11):1305-10. PubMed ID: 21051315
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapies: going beyond their limits.
Moserle L; Jiménez-Valerio G; Casanovas O
Cancer Discov; 2014 Jan; 4(1):31-41. PubMed ID: 24356098
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.
Basu B; Biswas S; Wrigley J; Sirohi B; Corrie P
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1583-98. PubMed ID: 19895243
[TBL] [Abstract][Full Text] [Related]
19. Tumor vasculature: the Achilles' heel of cancer?
Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.
Wei XW; Zhang ZR; Wei YQ
Expert Opin Investig Drugs; 2013 Sep; 22(9):1181-92. PubMed ID: 23782133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
